rss
Br J Ophthalmol 93:1
  • At a glance

At a glance

VEGF trap-eye for diabetic macular oedema

VEGF Trap is a human recombinant fusion protein consisting of the binding domains of VEGF receptors and Fc domain of IgG. Compared with ranibizumab, VEGF Trap has a longer half-life after intraocular injection, a higher binding affinity to VEGF-A, and binds other members of the VEGF family. Do et al assessed the safety and bioactivity of a single intravitreal injection of VEGF Trap-Eye (4.0 mg) in five subjects with diabetic macular oedema. No ocular toxicity was observed. At 6 weeks, four of the five patients showed improvement in foveal thickness (31% reduction from baseline) and improvement in BCVA (three letters).

See pages 144

Intravitreal bevacizumab for myopic choroidal neovascularisation

Choroidal neovascularisation is one of the significant sight-threatening complications in pathological myopia. Chan et al performed a prospective study to examine the 1-year results of intravitreal bevacizumab in 29 patients with myopic CNV. The patients received 3 initial monthly injections; additional monthly injections were performed in …

Relevant Articles

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.